Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically

REFERENCES

• Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221–1231
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelina-tion. Ann Neurol 2000; 47: 707–717
   PubMed Web of Science ®Google Scholar
• Compston A. The genetic epidemiology of multiple sclerosis. Phil Trans R Soc Lond 1999; 354: 1623–1634
   PubMed Web of Science ®Google Scholar
• Coo H, Aronson KJ. A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology 2004; 23: 1–12
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–127
   PubMed Web of Science ®Google Scholar
• Steinman L. Multiple sclerosis: A two-stage disease. Nat Immunol 2001; 2: 762–764
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285
   PubMed Web of Science ®Google Scholar
• Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobul in in Multiple Sclerosis Study Group. Lancet 1997; 349: 589–593
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50: 1273–1281
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. Eur J Neurol 2002; 9: 557–563
   PubMed Web of Science ®Google Scholar
• Hurez V, Kazatchkine MD, Vassilev T, et al. Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experi-mental autoimmune disease. Blood 1997; 90: 4004–4013
   PubMed Web of Science ®Google Scholar
• Rossi F, Dietrich G, Kazatchkine M. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135–149
   PubMed Web of Science ®Google Scholar
• Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484–486
   PubMed Web of Science ®Google Scholar
• Stangel M, Joly E, Scolding NJ, et al. 2000 Normal polyclonal immunoglobulins (Wig) inhibit microglial phagocytosis in vitro. J Neuroimmunol 2000; 106: 137–144
   Web of Science ®Google Scholar
• Stangel M, Compston A, Scolding NJ. Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (IVIg). J Neuroimmunol 2000; 103: 195–201
   PubMed Web of Science ®Google Scholar
• Basta M, Langlois PF, Marques M, et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clear-ance. Blood 1989; 74: 326–333
   PubMed Web of Science ®Google Scholar
• Rodriguez M. Immunoglobulins stimulate central nervous system remyelination: Electron microscopic and morphometric analysis of proliferating cells. Lab Invest 1991; 64: 358–370
   PubMed Web of Science ®Google Scholar
• Warrington AE, Asakura K, Bieber AJ, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000; 97: 6820–6825
   PubMed Web of Science ®Google Scholar
• Bradl M, Hohlfeld R. Molecular pathogenesis of neuroinflamma-tion. J Neurol Neurosurg Psychiatry 2003; 74: 1364–1370
   PubMed Web of Science ®Google Scholar
• Tanuma N, Shin T, Matsumoto Y. Characterization of acute versus chronic relapsing autoimmune encephalomyelitis in DA rats. J Neuroimmunol 2000; 108: 171–180
   PubMed Web of Science ®Google Scholar
• Lorentzen JC, Issazadeh S, Storch M, et al. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995; 63: 193–205
   PubMed Web of Science ®Google Scholar
• Kornek B, Storch MK, Weissert R, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantita-tive study of axonal injury in active, inactive, and remyelinated lesions. Am] Pathol 2000; 157: 267–276
   PubMed Web of Science ®Google Scholar
• Wujek JR, Bjartmar C, Richer E, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. ] Neuropathol Exp Neurol 2002; 61: 23–32
   PubMed Web of Science ®Google Scholar
• Pashov A, Dubey C, Kaveri SV, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by indu-cing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 1998; 28: 1823–1831
   PubMed Web of Science ®Google Scholar
• Achiron A, Mor F, Margalit R, et al. Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. J Autoimmun 2000; 15: 323–330
   PubMed Web of Science ®Google Scholar
• Kaveri S, Prasad N, Vassilev T, et al. Modulation of autoimmune responses by intravenous immunoglobul in (IVIg). Mult Scler 1997; 3: 121–128
   PubMed Web of Science ®Google Scholar
• Amran D, Renz H, Lack G, et al. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglo-bulin. Clin Immunol Immunopathol 1994; 73: 180–186
   PubMedGoogle Scholar
• Aktas O, Waiczies S, Grieger U, et al. Polyspecific immunoglo-bulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol 2001; 114: 160–167
   PubMed Web of Science ®Google Scholar
• Andersson UG, Bjork L, Skansen-Saphir U, et al. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993; 79: 211–216
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Warrington A, Pease LR, et al. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001; 24: S39—S44
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Lennon VA. Immunoglobulins promote remyelina-tion in the central nervous system. Ann Neurol 1990; 27: 12–17
   PubMed Web of Science ®Google Scholar
• Stangel M, Boegner F, Klatt CH, et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobu-lins in multiple sclerosis. ] Neurol Neurosurg Psychiatry 2000; 68: 89–92
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinat-ing optic neuritis. Neurology 2001; 56: 1514–1522
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. TAR IMS study group. Neurology 2004; 63: 2028–2033
   PubMed Web of Science ®Google Scholar
• Achiron A, Gabbay U, Gilad R, et al, Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50: 398-402
   Google Scholar
• Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9: 565–572
   PubMed Web of Science ®Google Scholar
• Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immuno-globulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149–1156
   PubMed Web of Science ®Google Scholar